Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease

PURPOSE: Efficacy and safety of agalsidase alfa at 0.2 mg/kg weekly were compared with 0.2 mg/kg every other week (EOW). Exploratory analyses were performed for 0.4 mg/kg weekly. PATIENTS AND METHODS: This was a 53-week, Phase III/IV, multicenter, open-label study (NCT01124643) in treatment-naïve ad...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Drug Des Devel Ther
Autori principali: Goláň, Lubor, Goker-Alpan, Ozlem, Holida, Myrl, Kantola, Ikka, Klopotowski, Mariusz, Kuusisto, Johanna, Linhart, Aleš, Musial, Jacek, Nicholls, Kathleen, Gonzalez-Rodriguez, Derlis, Sharma, Reena, Vujkovac, Bojan, Chang, Peter, Wijatyk, Anna
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2015
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4501226/
https://ncbi.nlm.nih.gov/pubmed/26185417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S80928
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi